Complementation of function after coexpression of pairs of nonfunctional G protein-coupled receptors that contain distinct inactivating mutations supports the hypothesis that such receptors exist as dimers. Chimeras between members of the metabotropic glutamate receptor-like family have been particularly useful because the N-terminal ligand binding and heptahelical transmembrane elements can be considered distinct domains. To examine the utility of a related approach for opioid receptors, fusion proteins were generated in which a pertussis toxin-resistant (Cys Extensive literature now exists on the capacity of a wide range of G protein-coupled receptors (GPCRs) to form dimers and/or higher-order oligomers (Lee et al., 2003; Breitwieser, 2004; Milligan, 2004) . Despite this, many of the reports have been predominantly descriptive and provide limited insights into the proportion of different GPCRs that may exist as dimers, the relative propensity of different GPCRs to oligomerize, the molecular basis of dimerization, and whether there are differences in the details of how closely related GPCRs form dimers/oligomers.
of the receptors to G i1 ␣Gly 202 Ala,Cys 351 Ile or mutation of a pair of conserved Val residues in intracellular loop 2 of each receptor. Coexpression, but not simple mixing, of the two inactive fusion proteins reconstituted agonist-loading of [
35 S]GTP␥S for each receptor. At equimolar amounts, reconstitution of DOP receptor function was more extensive than or opioid receptor. Reconstitution of DOP function required two intact receptors and was not achieved by provision of extra G i1 ␣Cys 351 Ile membrane anchored by linkage to DOP transmembrane domain 1. Inactive forms of all G protein ␣ subunits can be produced by mutations equivalent to G i1 ␣Gly 202 Ala. Because the amino acids modified in the opioid receptors are highly conserved in most rhodopsin-like receptors, this approach should be widely applicable to study the existence and molecular basis of receptor dimerization.
Extensive literature now exists on the capacity of a wide range of G protein-coupled receptors (GPCRs) to form dimers and/or higher-order oligomers (Lee et al., 2003; Breitwieser, 2004; Milligan, 2004) . Despite this, many of the reports have been predominantly descriptive and provide limited insights into the proportion of different GPCRs that may exist as dimers, the relative propensity of different GPCRs to oligomerize, the molecular basis of dimerization, and whether there are differences in the details of how closely related GPCRs form dimers/oligomers.
The ability of the DOP, KOP, and MOP opioid receptor subtypes to form homodimers and/or higher-order oligomers has previously been investigated using both coimmunoprecipitation and resonance energy transfer techniques (Cvejic and Devi, 1997; George et al., 2000; McVey et al., 2001; Li-Wei et al., 2002; Ramsay et al., 2002) . Despite this, little information is available on the issues noted above, although informatic analysis has suggested potential interfaces in transmembrane helices that may contribute to opioid receptor subtype homodimerization (Filizola and Weinstein, 2002) .
If coexpression of two nonequivalent and nonfunctional mutants of a GPCR is both able and required to reconstitute receptor ligand binding and/or function, this can provide evidence in favor of direct protein-protein interactions and quaternary structure for the active receptor (Milligan and Bouvier, 2005) . For example, coexpression of two forms of the angiotensin AT1 receptor that were unable to bind angiotensin II or related ligands because of point mutations in transmembrane region III or V restored ligand binding (Monnot et al., 1996) . Such an approach has also been used to explore mechanisms of dimerization. Theoretical models of GPCR dimerization include both "contact" and "domain swap" dimers. Using the histamine H1 receptor as a model, Bakker et al. (2004) showed that although single point mutations in both transmembrane region III and transmembrane region VI prevented binding of antagonist radioligands, including [ 3 H]mepyramine, coexpression of the two mutants resulted in reconstitution of [ 3 H]mepyramine binding sites with the anticipated pharmacological characteristics. From a conceptual standpoint, this should not be possible for a contact dimer in which transmembrane domains are not exchanged but simply appose each other.
In addition to the restoration of ligand binding, studies that have used pairs of nonfunctional mutants to restore GPCR signaling have produced data consistent with GPCR-GPCR interactions. By generating mutants of the luteinizing hormone receptor that were either unable to bind ligand or unable to signal but able to bind the agonist, Lee et al. (2002) were able to reconstitute agonist-mediated regulation of cAMP levels after coexpression of the two mutants. The luteinizing hormone receptor, as with other GPCRs with related ligands, has an extended N-terminal region involved in ligand binding. As such, Lee et al. (2002) were able to consider the N-terminal "exo-domain" and the seven transmembrane element "endo-domain" as distinct entities in a manner equivalent to the extracellular and transmembrane elements of class C GPCRs, which has allowed elegant chimeric receptor approaches to understand the mechanism of signal transduction through obligate heterodimers (Pin et al., 2005) .
As a variant of this, functional complementation was recently observed after the coexpression of pairs of ␣ 1b -adrenoceptor-G 11 ␣ and histamine H1 receptor-G 11 ␣ GPCR-G protein fusion proteins that were both inactive when expressed individually because they contained specific mutations in either the GPCR or G protein element (Carrillo et al., 2003) . All G protein ␣ subunits contain a conserved Gly that, when mutated, prevents effective GDP-GTP exchange and hence activation . Furthermore, nearly all class A, rhodopsin-like GPCRs have one or, more usually, two hydrophobic residues in the second intracellular loop homologous to those mutated to generate inactive forms of the ␣ 1b -adrenoceptor and histamine H1 receptor . We thus wished to test whether equivalent pairs of inactive opioid receptor-G i ␣ fusion proteins could be produced and to assess whether variations in pharmacology and/or reconstitutive capacity could provide insights into the basis of opioid receptor subtype dimerization. Antibodies/Antisera. The anti-G␣ i1-2 antiserum (SG) has been described previously (Green et al., 1990) . The mouse monoclonal anti-Flag antibody (M2) was from Sigma-Aldrich. The rabbit polyclonal anti-c-myc antiserum was from Cell Signaling Technology (Nottingham, UK) Molecular Constructs. hDOP-G i1␣ C 351 I in pcDNA3.1 was generated previously (Moon et al., 2001 ) and used as a template to introduce mutations in the 2 nd intracellular loop of the receptor to produce hDOPV 150 E,V 154 D-G i1␣ C 351 I using the QuikChange kit (Stratagene, La Jolla, CA) and the following primers: sense, 5Ј-GAC CGC TAC ATC GCT GAG TGC CAC CCT GAC AAG GCC CTG GAC TTC-3Ј; antisense, 5Ј-GAA GTC CAG GGC CTT GTC AGG GTG GCA CTC AGC GAT GTA GCG GTC-3Ј. Bold letters indicate altered bases. The PCR product was then digested with DpnI and transformed into bacteria.
Materials and Methods

Materials
hDOP-G i1␣ G 202 A,C 351 I. In a similar manner, hDOP-G i1␣ C 351 I was used to introduce the G 202 A mutation in G i1␣ using the following primers: sense, 5Ј-G TTT GAC GTG GGA GCC CAG AGA TCA GAG C-3Ј; antisense, 5Ј-G CTC TGA TCT CTG GGC TCC CAC GTC AAA C-3Ј. The PCR product was then digested by DpnI and was transformed into bacteria.
Flag-hDOPV 150 E,V 154 D-G i1␣ C 351 I. Flag-hDOPV 150 E,V 154 D-G i1␣ C 351 I was constructed using the following primers: sense, 5Ј-ACT AGT GCT AGC ATG GAC TAC AAG GAC GAC GAT GAT AAG GAA CCG GCC CCC TCC GCC GGC-3Ј; antisense, 5Ј-GAA TTT GGA TCC GGC GGC AGC GCC ACC GCC GGG-3Ј. The sense primer contains a Flag sequence (in bold) and an NheI restriction site (underlined) and corresponds to the N-terminal region of hDOP. The antisense primer contains a BamHI site (underlined) and corresponds to the C-terminal region of hDOP. The PCR product and pcDNA3.1 vector containing hDOPV 150 E,V 154 D-G i1␣ C 351 I were digested by NheI and BamHI. The digested products were then ligated.
c-myc-hDOP-G i1␣ G 202 A,C 351 I. c-myc-hDOP-G i1␣ G 202 A,C 351 I was constructed using the following primers: sense, 5Ј-CCC TTT GCT AGC ATG GAA CAA AAG CTT ATT TCT GAA GAA GAT CTG GAA CCG GCC CCC TCC GCC-3Ј; antisense, 5Ј-GAA TTT GGA TCC GGC GGC AGC GCC ACC GCC GGG-3Ј. hDOP-G i1␣ G 202 A,C 351 I was amplified by these primers. The sense primer contains a c-myc sequence (bold) and NheI restriction site (underlined), and the antisense primer contains a BamHI site (underlined). The PCR product and pcDNA3.1 containing hDOP-G i1␣ G 202 A,C 351 I were digested with NheI and BamHI. The digested products were then ligated. hMOPV 169 EV 173 D-G i1␣ C 351 I. hMOR-G i1␣ C 351 I cDNA in pcDNA3 was generated previously (Massotte et al., 2002) and was used as a template to introduce mutations in the 2nd intracellular loop of the receptor using the following primers: sense, 5Ј-GAT CGA TAC ATT GCA GAG TGC CAC CCT GAC AAG GCC TTA GAT TTC-3Ј; antisense, 5Ј-GAA ATC TAA GGC CTT GTC AGG GTG GCA CTC TGC AAT GTA TCG ATC-3Ј. The appropriate valines were mutated into glutamate (GAG) and aspartate (GAC), respectively. Altered bases mutated are in bold. The PCR product was digested by DpnI and was transformed into bacteria. rKOP-G i1␣ C 351 I. rKOP-G i1␣ C 351 I was constructed using the following primers: sense, 5Ј-CCC AAA AAG CTT ATG GAG TCC CCC ATC CAG ATT TTC C-3Ј; antisense, 5Ј-GGC ATC GGT ACC TAC TGG CTT ATT CAT CCC ACC CAC ATC CCT CAT GGA-3Ј. Rat KOP was amplified between these primers corresponding to the N and C termini of rKOP and containing HindIII and KpnI restriction sites (underlined). The PCR product and pcDNA3 containing G i1␣ C 351 I were digested by the above enzymes. Because rKOP contains an internal HindIII site, a two-way ligation was performed to ligate the vector and the two elements of the digested PCR product.
rKOP V 160 E,V 164 D-Gi 1␣ C 351 I. rKOP-G i1␣ C 351 I cDNA, as above, was used as a template to introduce mutations in the 2nd intracellular loop of the receptor, using the following primers: sense, 5Ј-GAC CGC TAC ATT GCC GAG TGC CAC CCT GAC AAA GCT TTG GAT TTC-3Ј; antisense, 5Ј-GAA ATC CAA AGC TTT GTC AGG GTG GCA CTC GGC AAT GTA GCG GTC-3Ј. Bases mutated are in bold.
rKOP-Gi 1␣ G 202 A,C 351 I. rKOP-G i1␣ C 351 I cDNA was used as a template to introduce the mutation in G i1␣ as for hDOP and hKOP.
Flag-Nt-TM1-G i1␣ C 351 I. Flag-Nt-TM1-G i1␣ C 351 I was constructed using the following primers: sense, 5Ј-ACT AGT GCT AGC ATG GAC TAC AAG GAC GAC GAT GAT AAG GAA CCG GCC CCC TCC GCC GGC-3Ј: sense, 5Ј-CCC ATT GGA TCC GGT GGC CGT CTT CAT CTT AGT GTA CCG-3Ј. Flag-hDOP-G i1␣ C 351 I was used as template for PCR. The first 252 base pairs were amplified by PCR and were then digested using BamHI and NheI (restriction sites underlined). The same digestion was used on the template, NheI being situated at the end of the receptor sequence. PCR products and vector were ligated.
Cell Transfection and Treatment. HEK293 cells were transfected using Lipofectamine reagent (Invitrogen, Carlsbad, CA) or Gene Juice (Novagen, Madison, WI) and the appropriate cDNA(s) according to the manufacturers' instructions. Cells were treated with pertussis toxin (25 ng/ml) for 16 to 18 h before harvest.
[ 3 H]Diprenorphine Binding. The expression of GPCR-G protein fusions was assessed by measuring the specific binding of [ 3 H]diprenorphine in cell membrane preparations. Nonspecific binding was assessed by the addition of 100 M naloxone. Samples were incubated for 1 h at 25°C, and bound ligand was separated from free by vacuum filtration through GF/B filters (Whatman, Maidstone, UK) pretreated with 0.3% polyethylenimine in 10 mM Tris/HCL, 0.1 mM EDTA, and 10 mM MgCl 2 , pH adjusted to 7.5. Bound ligand was estimated by liquid scintillation counting. Competition studies were conducted with 1 nM [ 3 H]diprenorphine and a range of concentrations of other ligands. Data were analyzed using Prism (GraphPad Software, San Diego, CA). Saturation data were fit to nonlinear regression curves.
[ 35 S]GTP␥S Binding Studies. Experiments were initiated by adding the assay buffer mix (20 mM HEPES, pH 7.4, 3 mM MgCl 2, 100 mM NaCl, 10 M GDP, and 0.2 mM ascorbic acid) containing 50 nCi of [
35 S]GTP␥S in the presence or absence of agonist to a defined amount of membranes. Nonspecific binding was determined in the presence of 100 M GTP␥S. The reaction was incubated for 15 min at 30°C and terminated by adding 1 ml of ice-cold stop buffer. The samples were centrifuged for 15 min at 16,000g at 4°C, and the resulting pellets were resuspended in solubilization buffer (100 mM Tris HCl, 200 mM NaCl, 1 mM EDTA, 1.25% Nonidet P40, pH adjusted to 7.4) plus 0.2% SDS. Samples were precleared with Pansorbin for 1 h at 4°C and centrifuged for 2 min at 16,000g. Supernatant was added to a mix of protein G and the anti-G i1␣ /G i2␣ antiserum, SG (Green et al., 1990) , and left rotating overnight at 4°C for immunoprecipitation. The immunocomplexes were washed twice with ice-cold solubilization buffer, and bound [
35 S]GTP␥S was measured.
Coimmunoprecipitation. Cells were resuspended in 1 ml of 1ϫ radioimmunoprecipitation assay buffer and rotated for 60 min at 4°C to allow lysis. The samples were centrifuged at 14,000g for 10 min at 4°C, and the supernatant was retained. Fifty microliters of a protein G-Sepharose/phosphate-buffered saline slurry was added to the supernatant and rotated for a further 60 min at 4°C to preclear. Samples were centrifuged at 14,000g for 10 min at 4°C. Supernatant was conserved, and protein concentration was measured using the BCA assay method. Samples were equalized to 1 g/l. Target proteins were then immunoprecipitated from 500-l samples by incubation with 20 l of protein G-Sepharose and the appropriate antibody/antiserum overnight at 4°C on a rotating wheel. Immune complexes were isolated by centrifugation at 14,000g for 1 min and washed twice with radioimmunoprecipitation assay buffer. Proteins were eluted from the protein G-Sepharose by the addition of 30 to 50 l of Laemmli buffer and heated for 4 min at 85°C. The eluates were then loaded onto SDS-PAGE gels.
Quantitation of I-expressing cell membranes was greatly increased by DADLE, the construct was also able to load [ 35 S]GTP␥S in the absence of agonist (Fig. 1A) . When membrane amounts corresponding to varying levels of hDOP-G i1␣ C 351 I were used, DADLE stimulation of [ 35 S]GTP␥S binding was linear with fusion protein amount over the full range tested and up to at least 60 fmol (Fig. 1B) .
We have demonstrated previously that mutation of Gly   208 to Ala in the G protein G 11␣ prevents receptor-mediated guanine nucleotide exchange and hence [ 35 S]GTP␥S binding (Carrillo et al., 2002) . The ␣ subunit of all heterotrimeric G proteins contains Gly at the equivalent position. To test the general effect of mutating this Gly on the capacity of receptors to enhance guanine nucleotide exchange, we thus gen- (Fig. 2) . Furthermore, [
35 S]GTP␥S loading in the absence of DADLE was substantially reduced (Fig. 2) . Mutation of hydrophobic residues in the second intracellular loop of family A GPCRs can essentially eliminate G protein activation without major effects on antagonist ligand binding (Carrillo et al., 2003 . To test whether mutation of the equivalent amino acids eliminated G protein activation for hDOP, we also generated hDOPV 150 (Fig. 2) (Fig. 2) or with the equivalent levels of expression of these two constructs when expressed individually (Table 1) Immunoprecipitation with anti-Flag antibody followed by SDS-PAGE and immunoblotting with anti-c-myc antibody resulted in detection of specific c-myc immunoreactivity only when the two fusion constructs were coexpressed (Fig. 3) , consistent with a physical interaction between the two variants.
To further explore aspects of pharmacology of the fusion proteins, membranes from pertussis toxin-treated HEK 293 cells transfected to express hDOP-G i1␣ C (Table 2) . Two-site binding curves reflecting higher and lower affinity binding sites for the agonist DADLE were best fitted in each case. Introduc- (Table 3) . Although a similar trend was observed for the low-affinity site ( (Fig. 4A) . Likewise, the prototypic opioid receptor antagonist naloxone was equipotent in its ability to prevent DADLE-stimulated [ ing interactions between hDOPV 150 E,V 154 D and hDOP, we generated and expressed a construct (Flag-Nt-TM1-G i1␣ C 351 I) in which G i1␣ C 351 I was linked to a sequence comprising the N-terminal domain, transmembrane region 1, and the first intracellular loop of hDOP. This construct did not bind [
3 H]diprenorphine (data not shown), but its expression as an apparent 48-kDa polypeptide could clearly be detected by immunoblotting transfected HEK293 membranes with the anti-G i1␣ /G i2␣ antiserum (Fig. 5A) . Parallel SDS-PAGE and immunodetection of varying amounts of recombinantly expressed G i1␣ , followed by densitometry of the signals, allowed production of a standard curve for G i1␣ expression that was linear over the range (0 -50 ng) employed. Based on the anti-G i1␣ immunological signal in membranes corresponding to Flag-Nt-TM1-G i1␣ C 351 I and its calculated molecular mass (49.3 kDa), we estimated levels of this construct to be 13.8 pmol/mg of membrane protein. Therefore, this construct was present at some six times the level of the hDOP-G i1␣ fusion proteins. Cotransfection of Flag-Nt-TM1-G i1␣ C 351 I with hDOP-G i1␣ G 202 A,C 351 I resulted in very low but statistically significant increases in levels of [
35 S]GTP␥S binding in anti-G i1␣ /G i2␣ antiserum immunoprecipitates when DADLE was added to such membranes (Fig. 5B) . These very small signals did not reflect the possibility that although hDOP-G i1␣ G 202 A,C 351 I and Flag-Nt-TM1-G i1␣ C 351 I were coexpressed, they were present in distinct membrane compartments. Coexpression of Flag-Nt-TM1-G i1␣ C 351 I with c-mychDOP-G i1␣ G 202 A,C 351 I allowed their coimmunoprecipitation (Fig. 6A) , indicating not only proximity but also their capacity for physical interactions. Likewise, coexpression of c-mycNt-TM1 with the isolated Flag-hDOP allowed their coimmunoprecipitation, indicating interactions were not a reflection of contacts between the two copies of the G protein (Fig. 6B) .
To extend these reconstitution studies to the other opioid receptors we generated equivalent fusion proteins incorporating the human MOP-1 (hMOP) receptor. DAMGO binding were akin to a mixture of the two mutant constructs (Fig. 8, Table 5 ), and analysis of the binding curves was consistent with the presence of the two constructs at a ratio of nearly 1:1. Studies were also performed on the rat (r)KOP receptor. rKOP-G i1␣ C 351 I, rKOP-G i1␣ G 202 A,C 351 I, and rKOPV 160 -E,V 164 D-G i1␣ C 351 I fusions were generated and expressed. These also all bound [ 3 H]diprenorphine with high affinity and expressed to similar levels (Table 6) ; however, as with the hDOP constructs, a reduction in affinity was recorded for the rKOPV 160 E,V 164 D-G i1␣ C 351 I construct that incorporated mutations into the second intracellular loop of the receptor. As with the equivalent hDOP and hMOP constructs, rKOP-G i1␣ C 351 I allowed a large increase in [ 35 S]GTP␥S binding in response to agonist treatment (Fig. 9) (Fig. 9) . At a maximally effective concentration of U69593 (10 M), membranes expressing twice as many rKOP [ 3 H]diprenorphine binding sites, after coexpression of the two inactive mutants, allowed approximately 50% of the amount of agonist-stimulated [ 35 S]GTP␥S binding generated by wild-type rKOP-G i1␣ C 351 I fusion (Fig. 9) . As with the hMOP constructs, in competition studies between [ 3 H]diprenorphine and U69593, both rKOP-G i1␣ C 351 I and rKOP-G i1␣ G 202 A,C 351 I displayed both highand low-affinity binding sites for the agonist. However, rKOPV 160 E,V 164 D-G i1␣ C 351 I displayed only a single, low-affinity site for U69593 (Fig. 10, Table 7 ). In addition, as with the hMOP constructs, coexpression of rKOPV 160 E,V 164 D-G i1␣ C 351 I and rKOP-G i1␣ G 202 A,C 351 I resulted in a pattern of U69593 binding consistent with a mixture of the pharmacology of the two constructs (Fig. 10, Table 7 ). The potency of U69593 to activate rKOP-G i1␣ C 351 I (pEC 50 ϭ 7.3 Ϯ 0.08) was higher (p Ͻ 0.05) than that for the reconstituted rKOP dimer (pEC 50 ϭ 6.8 Ϯ 0.13).
Discussion
Fusion proteins between GPCRs and G protein ␣ subunits have been used to examine a wide range of function of these polypeptides (Milligan, 2002; Milligan et al., 2004) . The defined 1:1 stoichiometry of the partner proteins is of particular use in measures of agonist-induced GTPase turnover number (Moon et al., 2001 ) and the regulation [coordinated (Stevens et al., 2001) or otherwise (Barclay et al., 2005) ] of posttranslational thioacylation of GPCR and G protein and the effects of mutations in either partner that alter protein steady-state expression levels (Ward and Milligan, 2002) . In the current studies, we have generated and explored the function and pharmacology of fusions between each of the DOP, KOP, and MOP opioid receptors with G i1␣ . The functionality of each of these mutants was established in [ 35 S]GTP␥S binding studies in which immunoprecipitation with an anti-G i1␣ /G i2␣ antiserum limited nonspecific binding of the nucleotide at assay termination. All commonly used cell lines express members of the G i␣ G protein family that are substrates for pertussis toxin-catalyzed ADP-ribosylation. To ensure that agonist-driven [
35 S]GTP␥S binding reflected only binding to the fusion proteins under study, they were constructed using G i1␣ C 351 I (Bahia et al., 1998) , which is insensitive to the actions of the toxin but able to be effectively activated by receptors, and by treating cells with pertussis toxin before cell harvest to modify the endogenous G i␣ pool. Mutation of Gly 202 to Ala in G i1␣ resulted in a form of the G protein that was unable to exchange guanine nucleotide and bind [
35 S]GTP␥S in response to receptor agonists. All G protein ␣ subunits have a Gly residue in the equivalent position, and mutation should therefore be anticipated to produce equivalent lack of function mutants, as shown previously for G 11␣ (Carrillo et al., 2002 (Carrillo et al., , 2003 . Fusion of wildtype G 11␣ to forms of the ␣ 1b -adrenoceptor and the histamine H1 receptor containing hydrophobic-to-acidic residue mutations in intracellular loop 2 also results in lack of agonistmediated [
35 S]GTP␥S binding without destruction of the ligand binding pocket (Carrillo et al., 2003) . Because most rhodopsin-like GPCRs have a pair of homologous hydrophobic residues and in the DOP, KOP, and MOP receptors, both are Val, we converted each of these to either Glu or Asp. This did not alter construct expression (Carrillo et al., 2003) and have provided evidence that the reconstitution reflects an intermolecular rather than intramolecular interaction between GPCR and G protein (Carrillo et al., 2003) . Although expression of a single fusion protein, wild-type in both GPCR and G protein sequence, allows agonist mediated signal transduction, like expression of a single GPCR cDNA, this does not allow direct exploration of GPCR quaternary structure. Indeed, the knowledge that a single cDNA was generally sufficient to generate the anticipated function and pharmacology of a GPCR played a significant part in the expectation that GPCRs would be single polypeptide, monomeric structures (Milligan, 2004) . Previous studies by Molinari et al. (2003) also noted a capacity of coexpressed of pairs of inactive DOP-G protein fusions to reconstitute a signal. However, although they also concluded that dimerization reflected intermolecular interactions between the coexpressed forms, they did not specifically suggest that dimerization between the pair of DOP receptors was required. This may have been because they also observed an ability of a DOP-G protein fusion to activate a G protein that was membrane-anchored simply by linkage to transmembrane 1 of the vasopressin V2 receptor. In contrast with these observations, we observed only a very limited capacity of the hDOP-G i1␣ G 202 A,C 351 I construct to activate coexpressed G i1␣ C 351 I when it was tethered to the membrane by linkage to the N-terminal domain and transmembrane domain 1 of hDOP, even though the G protein was provided at levels approximately six times higher in this scenario than when provided by coexpression of the potentially complementary fusion protein. The basis for these differences is unclear but may relate to the high expression levels of the fusion proteins achieved and employed by Molinari et al. (2003) , which were in the range in which so called "bystander" interactions and effects have been observed (Mercier et al., 2002) , probably simply because of physical proximity rather than direct proteinprotein interactions. Although hDOP-G i1␣ G 202 A,C 351 I was unable to activate coexpressed Nt-TM1-G i1␣ C 351 I to any substantial extent, these two constructs were able to interact because they could be coimmunoprecipitated after coexpression. This suggests that interaction between two complete receptors might be required for GPCR function and would support other evidence for conformational alterations in the partner GPCR in a dimer induced by ligand binding (Mesnier and Baneres, 2004; El-Asmar et al., 2005) . Nt-TM1 could also Although homodimerization of each of these three receptors has previously been recorded (Cvejic and Devi, 1997; George et al., 2000; McVey et al., 2001; Li-Wei et al., 2002; Ramsay et al., 2002) , there is no useful information on the similarities or differences in mechanisms of these interactions that have involved direct experimental study, although this topic has been considered via an informatic approach (Filizola and Weinstein, 2002) . Although the mutation of hydrophobic residues in intracellular loop 2 may have limitations in producing an inactive GPCR, a marked advantage over certain other reconstitutive studies (Monnot et al., 1996; Bakker et al., 2004) is that the orthosteric GPCR ligand binding site was not destroyed. This allowed antagonist binding studies to confirm not only expression of each construct but also that each inactive mutant was expressed at the same level as the wild-type fusion. This was central to the "stochastic" calculations of the potential makeup of the GPCR dimer population generated after coexpression of different proteins. The complete conservation in G protein ␣ subunits of the Gly residue modified herein to generate one of the pair of inactive fusions and the very high conservation of the pair of GPCR intracellular loop hydrophobic residues suggest that this strategy should be widely applicable . For example, it is likely to be of considerable use in mutational studies designed to identify key residues involved in the dimerization interface(s) (Hernanz-Falcon et al., 2004) . Likewise, there is no reason to limit such studies to GPCR homodimerization and the effectiveness of functional reconstitution may provide quantitative data on the propensity of GPCRs to heterodimerize. Indeed, this has been initiated by studies showing that the histamine H1 receptor and the ␣ 1b -adrenoceptor are very poor interaction partners (Carrillo et al., 2003) . Finally, because only the reconstituted heterodimer is an active signaling unit, then in true GPCR heterodimerization studies, the functional pharmacology of the heterodimer could be examined without interfering signals generated by the corresponding coexpressed homodimers, which, as shown herein, are essentially inactive.
